Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.35 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1144387 | 0.74 | LMNA (0.36) | ADORA2AADORA1POLB | |
| SCHEMBL23400639 | 0.71 | ADORA2A (0.33) | ADORA2AADORA1ACHEADORA3AADAT | |
| SCHEMBL23398566 | 0.69 | ADORA2A (0.33) | ADORA2AADORA1ACHEAADAT | |
| SCHEMBL16026101 | 0.69 | ACHE (0.41) | ADORA2AADORA1ACHEADORA3AADAT | |
| SCHEMBL22649179 | 0.69 | SMN1; SMN2 (0.41) | ADORA2AADORA1ACHEADORA3AADAT | |
| SCHEMBL31226857 | 0.69 | ADORA2A (0.54) | ADORA2AADORA1ACHEADORA3AADAT | |
| SCHEMBL1144980 | 0.69 | NPC1 (0.47) | POLBHTT | |
| SCHEMBL15651613 | 0.68 | ADORA2A (0.56) | ADORA2AADORA1ACHEADORA3AADAT | |
| SCHEMBL22057946 | 0.68 | ADORA1 (0.39) | ADORA2AADORA1ACHEADORA3AADAT | |
| SCHEMBL8230261 | 0.68 | ADORA2A (0.36) | ADORA2AADORA1ACHEADORA3AADAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3888658-B1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230071483-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-03-09 | — | — | US | disclosed |
| US-20230071483-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-03-09 | — | — | US | disclosed |
| US-11440917-B2 | EIF4A-inhibiting compounds and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| CN-108601788-B | EIF 4A-inhibiting compounds and methods relating thereto | 效应治疗股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| EP-3888658-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | Effector Therapeutics Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3888658-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | Effector Therapeutics Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| WO-2017091585-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017091585-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
| US-20170145026-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170145026-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170145026-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| EP-2297163-B1 | Pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER (US) | 2015-07-08 | — | — | EP | disclosed |
| US-8318762-B2 | Pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2297163-A1 | PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS | Pfizer Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20110028390-A1 | Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| WO-2009144554-A1 | PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS | PFIZER, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | ADORA2A 3648/4885ADORA1 3350/4885ACHE 4751/4885 |
| US-20230071483-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | ADORA2A 3648/4885ADORA1 3350/4885ACHE 4751/4885 |
| US-11440917-B2 | EIF4A-inhibiting compounds and methods related thereto | EIF4A1, EIF4A2, EIF4A3 | ADORA2A 3648/4885ADORA1 3350/4885ACHE 4751/4885 |
| US-20110028390-A1 | Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | ADORA2A 3959/4885ADORA1 2488/4885ACHE 1167/4885 |
| US-20170145026-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | ADORA2A 3648/4885ADORA1 3350/4885ACHE 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.